Loading...
XSHE
000919
Market cap563mUSD
Jul 10, Last price  
6.13CNY
1D
2.34%
1Q
-22.70%
Jan 2017
-54.69%
Name

Jinling Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:000919 chart
P/E
70.71
P/S
1.19
EPS
0.09
Div Yield, %
1.63%
Shrs. gr., 5y
4.29%
Rev. gr., 5y
2.63%
Revenues
3.20b
-2.56%
1,966,705,7662,161,139,2872,257,022,7772,304,934,2202,605,713,7812,771,942,2853,221,375,3843,578,652,7733,191,811,8622,899,079,0222,899,079,0212,534,920,5392,503,732,3732,808,754,8762,808,754,8762,670,968,0382,670,968,0383,193,999,8533,281,450,5543,197,324,288
Net income
54m
+33.42%
220,957,624192,731,459165,201,943143,556,319155,890,352197,184,460208,109,274180,151,297137,126,469241,786,876241,786,884145,319,44365,136,499120,625,946120,625,952105,281,854105,281,859106,193,86540,409,79653,914,615
CFO
174m
+12.98%
138,503,706118,063,748305,263,648188,410,396177,809,117172,822,179232,116,926271,208,292299,891,714212,449,64196,149,992443,109,707433,825,968465,847,095311,464,432292,026,282260,590,694158,923,988154,190,609174,209,249
Dividend
Jul 08, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in the manufacture and distribution of a diverse range of pharmaceutical products. Its key offerings include the Mailuoning injection, prescribed for the management of numerous vascular and thrombotic conditions such as thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and its sequelae, multiple forms of arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis. The company also provides ferrous succinate tablets for the prevention and treatment of iron deficiency anemia, alongside lentinan injection used in the therapy of malignant tumors. Furthermore, Jinling Pharmaceutical offers medical health care services. The firm's operations are primarily based in Nanjing, China.
IPO date
Nov 18, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122019‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT